Company: XERI
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001477932-25-001010
Chunk: 30

Company: XERIANT, INC.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
 preference.

 F-21Table of Contents

Stock Options In connection with certain advisory board compensation agreements, the Company issued an aggregate 21,250,000 options at an exercise price of $0.12 per share for the year ended June 30, 2022. These options vest quarterly over twenty-four months and have a term of three years. The grant date fair value was $3,964,207. The Company recorded compensation expense in the amount of $0 and $515,917 for these options for the six months ended December 31, 2024 and 2023, respectively. As of June 30, 2024, there was $0 of total unrecognized compensation cost related to non-vested portion of options granted. As of December 31, 2024, there are 2,250,000 options outstanding, of which 2,250,000 are exercisable. The weighted average remaining term is 0.01 years. A summary of the Company’s stock options activity is as follows:   Number of Options   Weighted-Average Exercise Price  Weighted-Average Contractual Term(in years)  Aggregate Intrinsic Value Outstanding at June 30, 2024  21,250,000  $0.12   1.11    Granted  -            Exercised  -   -        Canceled  (19,000,000 )  -        Outstanding at December 31,2024  2,250,000  $0.12   0.01  $- Exercisable at December 31,2024  2,250,000  $0.12   0.01  $-  Significant inputs and results arising from the Black-Scholes process are as follows for the options: Quoted market price on valuation date $0.169 - $0.23 Exercise prices $0.12 Range of expected term 1.55 Years – 2.49 Years Range of market volatility:    Range of equivalent volatility 181.21% - 275.73% Range of interest rates 0.20% - 1.08% 

 F-22Table of Contents

Warrants As of December 31, 2024, and June 30, 2024, the Company had